Compare EQ & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQ | STXS |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.4M | 86.4M |
| IPO Year | 2018 | 2004 |
| Metric | EQ | STXS |
|---|---|---|
| Price | $1.28 | $0.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $8.56 | $2.67 |
| AVG Volume (30 Days) | 312.5K | ★ 881.2K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,095,000.00 | $29,346,617.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $35.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.16 | $0.80 |
| 52 Week High | $6.20 | $2.86 |
| Indicator | EQ | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 35.89 |
| Support Level | $1.24 | $0.80 |
| Resistance Level | $1.51 | $1.97 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 15.79 | 7.39 |
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.